RG7795

RG7795 ; ; ; ; ; ; ; ; ; ; ; ; ;
Legal status	Investigational
Identifiers
CAS Number	1174920-78-5 ; ; ; ; ; ; ; ; ; ; ; ; ;

RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.^[1] It is an orally-available prodrug of isatoribine,^[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.^[3] Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.^[2]

References[edit]

↑ RG 7795(link). AdisInsight.
↑ ^2.0 ^2.1 "Tickling the TLR7 to cure viral hepatitis.".Journal of Translational Medicine.14 May 2014;12
129.doi:10.1186/1479-5876-12-129.PMID:24884741.PMC:4039542.
↑ , Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration Full text, Genetic Engineering News, August 3, 2016,

RG7795[edit]

RG-7795
Isatoribine

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[Adis-1] RG 7795(link). AdisInsight.

[Funk-2] 2.0 ^2.1 "Tickling the TLR7 to cure viral hepatitis.".Journal of Translational Medicine.14 May 2014;12
129.doi:10.1186/1479-5876-12-129.PMID:24884741.PMC:4039542.

[3] , Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration Full text, Genetic Engineering News, August 3, 2016,

[1]

[2]

[3]